Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-22-055063)

Filing Details

Accession Number:: 0001209191-22-055063
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-11-01 17:00:14
Reporting Period:: 2022-10-28

Accepted Time:: 2022-11-01 17:00:14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1840574	Verve Therapeutics Inc.	VERV	Pharmaceutical Preparations (2834)	824800132

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1864116	Andrew Bellinger	C/O Verve Therapeutics, Inc. 201 Brookline Avenue, Suite 601 Boston MA 02215	Cso & Cmo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-10-28	10,000	$1.48	16,629	No	4	M	Direct
Common Stock	Disposition	2022-10-28	10,000	$39.90	6,629	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2022-10-28	10,000	$0.00	10,000	$1.48

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
86,995		2029-09-16	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2022.
The remaining shares underlying this option, which was granted on September 17, 2019, vest in equal monthly installments until October 1, 2023.